Drug Type Biosimilar, Monoclonal antibody |
Synonyms Recombinant chimeric anti-CD20 antibody(Shanghai Institute of Biological Products), 重组人鼠嵌合抗CD20单克隆抗体 (上海生物制品研究所), SIBP 02 + [3] |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| CD20 positive Diffuse Large B-Cell Lymphoma | China | 19 Mar 2024 | |
| Chronic Lymphocytic Leukemia | China | 19 Mar 2024 | |
| Follicular Lymphoma | China | 19 Mar 2024 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 11 Oct 2018 |






